Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis.
multiple sclerosis
neuroimmunology
optic neuritis
optical coherence tomography
serum neurofilament
translation
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
10
2020
accepted:
28
02
2021
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
10
6
2021
Statut:
epublish
Résumé
Serum neurofilament light chain (sNfL) and distinct intra-retinal layers are both promising biomarkers of neuro-axonal injury in multiple sclerosis (MS). We aimed to unravel the association of both markers in early MS, having identified that neurofilament has a distinct immunohistochemical expression pattern among intra-retinal layers. Three-dimensional (3D) spectral domain macular optical coherence tomography scans and sNfL levels were investigated in 156 early MS patients (female/male: 109/47, mean age: 33.3 ± 9.5 years, mean disease duration: 2.0 ± 3.3 years). Out of the whole cohort, 110 patients had no history of optic neuritis (NHON) and 46 patients had a previous history of optic neuritis (HON). In addition, a subgroup of patients ( In our cohort, HON patients had a thinner outer plexiform layer (OPL) volume compared to NHON patients ( In summary, sNfL levels were a good predictor of future outer retinal thinning in MS. Changes within the neurofilament-rich OPL could be considered as an additional retinal marker linked to MS neurodegeneration.
Sections du résumé
BACKGROUND
BACKGROUND
Serum neurofilament light chain (sNfL) and distinct intra-retinal layers are both promising biomarkers of neuro-axonal injury in multiple sclerosis (MS). We aimed to unravel the association of both markers in early MS, having identified that neurofilament has a distinct immunohistochemical expression pattern among intra-retinal layers.
METHODS
METHODS
Three-dimensional (3D) spectral domain macular optical coherence tomography scans and sNfL levels were investigated in 156 early MS patients (female/male: 109/47, mean age: 33.3 ± 9.5 years, mean disease duration: 2.0 ± 3.3 years). Out of the whole cohort, 110 patients had no history of optic neuritis (NHON) and 46 patients had a previous history of optic neuritis (HON). In addition, a subgroup of patients (
RESULTS
RESULTS
In our cohort, HON patients had a thinner outer plexiform layer (OPL) volume compared to NHON patients (
CONCLUSIONS
CONCLUSIONS
In summary, sNfL levels were a good predictor of future outer retinal thinning in MS. Changes within the neurofilament-rich OPL could be considered as an additional retinal marker linked to MS neurodegeneration.
Identifiants
pubmed: 34104217
doi: 10.1177/17562864211003478
pii: 10.1177_17562864211003478
pmc: PMC8155762
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562864211003478Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Front Neurol. 2019 Mar 12;10:205
pubmed: 30915022
J Comp Neurol. 2002 Nov 18;453(3):269-79
pubmed: 12378587
Neurology. 2003 Dec 23;61(12):1720-5
pubmed: 14694036
Neurology. 2016 Sep 13;87(11):1076-84
pubmed: 27521440
Neurology. 1976 Jun;26(6 PT 2):26-8
pubmed: 944889
Prog Retin Eye Res. 1999 Nov;18(6):737-63
pubmed: 10530750
Mult Scler. 2016 Apr;22(5):590-8
pubmed: 26283696
Mult Scler. 2016 Mar;22(3):362-72
pubmed: 26209589
Mult Scler. 2019 Apr;25(5):678-686
pubmed: 29542376
PLoS One. 2012;7(4):e34823
pubmed: 22536333
Brain. 2016 Nov 1;139(11):2855-2863
pubmed: 27581073
J Neurol. 2018 Oct;265(10):2284-2294
pubmed: 30073502
J Neurol. 2016 Jul;263(7):1323-31
pubmed: 27142714
Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491
pubmed: 30564615
J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):782-9
pubmed: 24474822
Mult Scler. 2015 Feb;21(2):163-70
pubmed: 24948688
Eur J Neurol. 2018 Apr;25(4):614-618
pubmed: 29272057
Neurol Neuroimmunol Neuroinflamm. 2019 Aug 12;6(5):
pubmed: 31454778
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Brain. 2012 Feb;135(Pt 2):521-33
pubmed: 22006982
Cell Tissue Res. 2015 Jun;360(3):609-20
pubmed: 25567110
Prog Retin Eye Res. 2014 Sep;42:44-84
pubmed: 24984227
Mult Scler. 2018 Aug;24(9):1196-1204
pubmed: 28669275
Acta Ophthalmol (Copenh). 1990 Apr;68(2):218-20
pubmed: 2356712
Int MS J. 2009 Sep;16(3):82-9
pubmed: 19878630
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Eur Radiol. 2015 Jan;25(1):122-31
pubmed: 25129119
PLoS One. 2017 Feb 13;12(2):e0172120
pubmed: 28192539
Mult Scler. 2020 Nov;26(13):1682-1690
pubmed: 31668116
Neurol Neuroimmunol Neuroinflamm. 2020 May 18;7(4):
pubmed: 32424064
Br J Ophthalmol. 2016 Apr;100(4):484-90
pubmed: 26307452
Ann Neurol. 2021 Jan;89(1):192-193
pubmed: 33067847
Vis Neurosci. 1994 May-Jun;11(3):501-17
pubmed: 8038125
Am J Ophthalmol. 1981 Jan;91(1):25-38
pubmed: 7234927
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
PLoS One. 2013 Aug 06;8(8):e71145
pubmed: 23940706
Lancet Neurol. 2012 Nov;11(11):963-72
pubmed: 23041237
J Neuroinflammation. 2019 Mar 11;16(1):59
pubmed: 30857557
Mult Scler. 2010 Mar;16(3):287-92
pubmed: 20086018
Brain. 2019 Apr 1;142(4):903-915
pubmed: 30847470
Ann Neurol. 2015 Mar;77(3):517-28
pubmed: 25559267
Ann Neurol. 2021 Jan;89(1):193-194
pubmed: 33068014
Mult Scler Relat Disord. 2021 Jan;47:102666
pubmed: 33291033
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223
Brain. 2010 Jun;133(Pt 6):1591-601
pubmed: 20410146
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Ann Neurol. 2020 Jun;87(6):885-896
pubmed: 32285484